Ujjaini Dasgupta

11PUBLICATIONS
33CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursPredictive and prognostic markersAllergy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Nov 20, 2025
Localized Hydrogel-Mediated Docetaxel-Carboplatin Combination Chemotherapy Targets Ganglioside Metabolism to Mitigate Tumor Progression.

Mohammad Nafees Ansari, Jasleen Kaur, Ali Khan

|Sep 11, 2025
The mTORC2 subunit RICTOR drives breast cancer progression by promoting ganglioside biosynthesis through transcriptional and epigenetic mechanisms.

Mohammad Nafees Ansari, Somesh K Jha, Ali Khan

|Feb 19, 2025
Docetaxel-conjugated bile acid-derived nanomicelles can inhibit tumour progression with reduced toxicity.

Devashish Mehta, Chhavi Dua, Ruchira Chakraborty

|Dec 19, 2024
Unveiling the Role of Mechanistic Target of Rapamycin Kinase (MTOR) Signaling in Cancer Progression and the Emergence of MTOR Inhibitors as Therapeutic Strategies.

Devashish Mehta, Kajal Rajput, Dolly Jain

|May 13, 2024
Engineered nanomicelles targeting proliferation and angiogenesis inhibit tumour progression by impairing the synthesis of ceramide-1-phosphate.

Poonam Yadav, Kajal Rana, Ruchira Chakraborty

|Jun 30, 2023
A localized hydrogel-mediated chemotherapy causes immunogenic cell death via activation of ceramide-mediated unfolded protein response.

Animesh Kar, Dolly Jain, Sandeep Kumar

Pageof 2

Frequent Collaborators

8 joint publications

Avinash Bajaj

6 joint publications

Devashish Mehta

4 joint publications

Kajal Rana

4 joint publications

Animesh Kar